Pediatric AML prognostication with an m6A-focused LASSO model

Acute myeloid leukemia (AML) presents varying prognoses in pediatric and adult patients, with dysregulated N6-methyladenosine (m6A)-related genes playing a pivotal role in its pathogenesis. Through an analysis of single-cell RNA sequencing data from the Gene Expression Omnibus, we uncovered distinct patterns of m6A gene expression specific to pediatric AML (pAML) cases. Additionally, we devised a LASSO risk regression model to evaluate prognosis within different AML subsets, showcasing the clinical utility of m6A-related genes in predicting AML outcomes. Our study underscores the unique and significant m6A gene expression profiles observed in pAML, emphasizing their potential relevance in prognostic assessment. The demonstrated effectiveness of the LASSO risk regression model further underscores the importance of m6A-related genes as valuable predictors of AML outcomes. These findings not only unveil novel insights into the prognostic implications of m6A-related genes in pAML but also advocate for their application as prognostic markers to enhance personalized treatment strategies in both pAML and adult AML populations.